Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025

Hexosylceramides are elevated in human, mouse and cellular Parkinson's disease and cause gene upregulations in neurons mimicking responses to pathogens

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLuisa FranckLHLisa HahnefeldLVLucie Valek

Discussion

Loading...

Member takes

Overview

Research demonstrates elevated glucosylceramides in Parkinson's disease, highlighting potential links to immune responses in neurons.

Key Points

  • Increased hexosylceramides and glucosylceramides are observed in human and animal models of parkinson's disease.
  • Lipidomic analyses reveal elevated glucosylceramide levels in the plasma of PD patients, indicating lysosomal dysfunction.
  • Accumulation of glucosylceramides in neurons triggered gene upregulation associated with immune responses.
  • Findings suggest that glucosylceramides could contribute to a proinflammatory state in the context of parkinson's disease.

Cite This Study

Franck et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfd55https://doi.org/10.21203/rs.3.rs-6633816/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Elevated hexosylceramides in Parkinson’s disease cause gene upregulations in neurons mimicking responses to pathogens2025 · 8 citations
  2. 2Plasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson’s disease pathogenesis2024 · 2 citations
  3. 3Glucosylceramide-induced ectosomes propagate pathogenic α-synuclein in Parkinson’s disease2026 · 7 citations
  4. 4Glucosylsphingosine affects mitochondrial function in a neuronal cell model2025 · 2 citations
  5. 5Inhibition or genetic reduction of <i>ASAH1</i> /acid ceramidase restore α-synuclein clearance in mutant <i>GBA1</i> dopamine neurons from Parkinson’s patients2025